Aspire Biopharma (ASBP) Stock Price, News & Analysis

Company Overview

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Key Stats

• Today's Range: $0.32 to $0.34
• 50-Day Range: $0.24 to $0.52
• 52-Week Range: $0.22 to $15.80
• Volume: 322,678 shs
• Average Volume: 965,418 shs
• Market Capitalization: $16.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASBP Stock Analysis - Frequently Asked Questions

How have ASBP shares performed this year?

Aspire Biopharma's stock was trading at $0.4301 on January 1st, 2025. Since then, ASBP shares have decreased by 21.9% and is now trading at $0.3360.

Who are Aspire Biopharma's major shareholders?

Aspire Biopharma's top institutional investors include Procyon Advisors LLC (1.31%), Crewe Advisors LLC (1.27%) and Optivise Advisory Services LLC (0.47%).

How do I buy shares of Aspire Biopharma?

Shares of ASBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASBP
• CIK: 1847345
• Web: N/A
• Phone: (561) 704-8527
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -508.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.17) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 49,530,000
• Free Float: 25,754,000
• Market Cap: $16.64 million
• Optionable: N/A
• Beta: 0.79